Cytokines and integrins related to inflammation of joint and gut in patients with spondyloarthritis and inflammatory bowel disease

Objectives Inflammatory bowel disease (IBD) and spondyloarthritis (SpA) have some overlapping clinical features, i.e. gut and joint inflammation. Cytokines of interleukin 17(IL-17)/IL-23 axis play a pathogenic role in both diseases. Integrins (ITGs) regulate migration of immune cells to inflamed tissues (ITGβ7 into gut, ITGβ2 into gut and also to other tissues). In this study, we search for differences in the serum concentrations of these cytokines and integrins between patients suffering from SpA or IBD with and without overlapping symptoms. Material and methods Patients with SpA (n = 30), IBD (n = 68), and healthy volunteers (n = 28) were included in the study. Fourteen SpA patients reported symptoms characteristic for IBD. Spondyloarthritis symptoms were diagnosed in 50% of IBD patients, while other patients of this group reported arthralgia only. Serum concentrations of IL-17, IL-22, IL-23, ITGβ2, and ITGβ7 were measured by specific enzyme-linked immunosorbent assay using commercially available sets. The Mann-Whitney and Spearman’s rank tests were used for intergroup comparison and correlation assessment, respectively. Results Comparison of patient groups showed significantly higher serum concentrations of IL-17, IL-22, and ITGβ7 in SpA, and up-regulated levels of IL-23 in IBD patients. Similar differences were observed between patient subgroups, both with and without overlapping symptoms. In SpA but not in IBD patients, serum concentrations of ITGβ7 inversely correlated (r = –0.552) with C-reactive protein. Conclusions Patients with SpA and IBD differ in the circulating concentrations of IL-17/IL-23 axis cytokines and ITGβ7, irrespectively of the presence or absence of overlapping symptoms. Therefore, we conclude that observed differences are attributed rather to underlying than concurrent disease.

[1]  J. Isaacs,et al.  Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? , 2017, Annals of the rheumatic diseases.

[2]  C. Prati,et al.  Spondyloarthritis: An expanding cast of cellular actors. , 2018, Joint, bone, spine : revue du rhumatisme.

[3]  P. Miossec Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice , 2017, RMD Open.

[4]  D. Wendling The gut in spondyloarthritis. , 2016, Joint, bone, spine : revue du rhumatisme.

[5]  E. Hauge,et al.  Changes in Soluble CD18 in Murine Autoimmune Arthritis and Rheumatoid Arthritis Reflect Disease Establishment and Treatment Response , 2016, PloS one.

[6]  E. Kontny,et al.  Inflammatory bowel disease-related arthritis – clinical evaluation and possible role of cytokines , 2015, Reumatologia.

[7]  E. Lubberts,et al.  The IL-23–IL-17 axis in inflammatory arthritis , 2015, Nature Reviews Rheumatology.

[8]  D. Dumitrascu,et al.  Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. , 2015, World journal of gastroenterology.

[9]  G. Sireci,et al.  Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis , 2015, Annals of the rheumatic diseases.

[10]  G. Hajishengallis,et al.  Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. , 2015, Pharmacology & therapeutics.

[11]  C. Prati,et al.  The IL-23/Th 17 pathway in spondyloarthritis: the royal road? , 2015, Joint, bone, spine : revue du rhumatisme.

[12]  A. Boonen,et al.  Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. , 2015, Annals of the rheumatic diseases.

[13]  E. Kontny New aspects of spondyloarthritis pathogenesis. Part III - arthritis, pathological bone remodeling Nowe aspekty patogenezy spondyloartropatii zapalnych. Część III - zapalenie stawów, patologiczna przebudowa kości , 2014 .

[14]  W. Robinson,et al.  Decreased plasma levels of soluble CD18 link leukocyte infiltration with disease activity in spondyloarthritis , 2014, Arthritis Research & Therapy.

[15]  Kori L Wallace,et al.  Immunopathology of inflammatory bowel disease. , 2014, World journal of gastroenterology.

[16]  P. Sarzi-Puttini,et al.  Rheumatic manifestations in inflammatory bowel disease. , 2014, Autoimmunity reviews.

[17]  T. Gheita,et al.  Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results , 2014, Clinical Rheumatology.

[18]  M. De Vos,et al.  Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model , 2012, Annals of the rheumatic diseases.

[19]  E. Raines,et al.  Metalloproteinase-mediated Shedding of Integrin β2 Promotes Macrophage Efflux from Inflammatory Sites* , 2011, The Journal of Biological Chemistry.

[20]  R. Straub,et al.  Integrins and their ligands in rheumatoid arthritis , 2011, Arthritis research & therapy.

[21]  M. Dougados,et al.  The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general , 2010, Annals of the rheumatic diseases.

[22]  T. Macdonald,et al.  IL‐23/IL‐17 axis in IBD , 2010, Inflammatory bowel diseases.

[23]  M. De Vos Joint Involvement Associated with Inflammatory Bowel Disease , 2009, Digestive Diseases.

[24]  F. Pallone,et al.  Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies. , 2009, World journal of gastroenterology.

[25]  D. Baeten,et al.  Ankylosing spondylitis and bowel disease. , 2002, Best practice & research. Clinical rheumatology.